|
|
|
市場調查報告書
耳鼻喉科疾病的市場 - 到2017年為止的預測: 頭孢菌素，奎諾酮類，巨環類抗生素取代了傳統治療方法
ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance
| 出版商 |
GBI Research |
| 出版日期 |
2012年01月 |
商品編碼 |
227588 |
| 內容資訊 |
英文 Pages: 165 |
| 價格 |
|
|
耳鼻喉科疾病的市場 - 到2017年為止的預測: 頭孢菌素，奎諾酮類，巨環類抗生素取代了傳統治療方法 是由出版商GBI Research在2012年01月所出版的。
這份英文市場調查報告書包含Pages: 165 價格從美金3500起跳。
全球耳鼻喉科疾病市場在2010年收益約為153億美金，預測2010-2017年將以年複利成長率1.6％增長，到2017年將達到172億美金的規模。
本報告以美國、歐洲五國、日本的耳鼻喉科疾病市場為調查對象，預測到2017年為止的治療法使用模式、銷售額、價格、出貨量、以及主要治療藥品部門相關的各地區預測，主要企業的競爭基準、合併、收購、授權契約等形成全球市場的要素分析，為您概述為以下內容。
第1章 目錄
第2章 簡介
第3章 市場概要
- 全球人口的增加和環境惡化促進耳鼻喉科疾病治療藥物
- 不平衡分配
- 濫用抗生素的耳鼻喉科疾病特徵
- 學名藥數受到FDA法規嚴格限制的新業者加入
- 收益預測
- 年度治療費用
- 治療方法的使用模式
- 耳鼻喉科疾病市場發展/阻礙因素
第4章 耳鼻喉科疾病市場:治療情形
- 扁桃腺炎市場
- 鼻竇炎市場
- 鼻炎市場
- 中耳炎市場
- 氣管支氣管炎市場
第5章 各地區情形
第6章 開發平台分析
第7章 競爭情形
第8章 策略性整合
第9章 附錄
圖表
Abstract
Summary
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
GBI Research's analysis shows that the ENT disorders market will continue to grow marginally, largely due to the growing population and deteriorating environmental conditions. The prime reasons for the slow growth of the market are the generic domination and the weak product pipelines for all five key indications.
The ENT disorders M&A landscape has seen low levels of activity over the last decade, with only 16 deals signed from 2004-2011. The therapeutic area of focus for the M&A deals from 2004-2011 remained highly concentrated for sinusitis. Some deals had multiple ENT disorders as their therapeutic area of focus.
Scope
- Annualized market data for the ENT disorders market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including tonsillitis, sinusitis, rhinitis, otitis media and tracheobronchitis.
- Analysis of the ENT disorders market in the leading geographies globally, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the ENT disorders market, including market size, annual cost of therapy and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in the various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Abbott Laboratories, Bayer AG, Eli Lilly, GSK, J&J, Novartis AG, Merck & Co., Pfizer and Sanofi.
- Key M&A activities and licensing agreements that have taken place between 2004 and mid-2011 in the global ENT disorders market
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms that can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Executive Summary
GBI Research, the leading business intelligence provider, has released its latest research, “ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance”, which provides in-depth analysis of the unmet needs, drivers and barriers that affect the global ENT disorders therapeutics market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and annual cost of therapy are forecast until 2017 for key geographies in the five leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.
Flooded by Generics ENT Disorders Therapeutics Market to Witness Meager Growth
The ENT disorder therapeutics market is flooded with several classes of generic drugs. Generic drugs are medications sold under a generic name that are only legal when the branded counterpart's patent expires or has no patent. They have the same formulation as the branded drugs and are launched to the market as and when the branded drug's patent expires. Generic versions of anti-bacterials including Pfizer's Zithromax (azithromycin), Abbott's Biaxin (clarithromycin), Johnson & Johnson's Levaquin (levofloxacin) and Bayer's Avelox (moxifloxacin) have captured the ENT therapeutics market. These generic drugs provide stiff competition to branded drugs, leading to an overall reduction in the market price of both branded and generic drugs. They are cost-effective both to patients and insurance companies as they cost on average 16% less than the branded varieties. Developing and under developed nations prefer importing generics. As the branded drugs have no protection once their patents expire, the cost of the drug eventually falls due to the competition posed by generic manufacturers. The ENT diseases generics market is dominated by companies such as Teva Pharmaceuticals, Mylan, Ranbaxy, and Watson.
The global ENT disorders market was estimated to be worth $15.3 billion in 2010, having grown at a compound annual growth rate (CAGR) of 0.7% between 2002 and 2010. By 2017, the global ENT disorders market is forecast to reach $17.2 billion, indicating a CAGR of 1.6% between 2010 and 2017. The slow growth in the market is attributed to high rate of saturation and considerable generic penetration. The primary reason for the growth rate is the increasing prevalence of ENT disorders. Sinusitis is one of the most commonly reported diseases in the US. Rhinitis is another indication that is on the rise due to mounting environmental pollutants.
The current ENT disorders pipeline does not offer any major promising or novel products. Therefore, the global ENT disorders market is expected to witness marginal overall growth in the future.
Short Drug Lifecycles Due to Antibacterial Overuse Restraints Companies to Invest in ENT Disorders Market
While antibiotics have been a life saver in fighting against serious bacterial infections for more than four decades now, they have been excessively prescribed, especially to children. According to Centers for Disease Control estimates, approximately 235 million doses of antibiotics are administered annually. About 20-50% of these prescriptions are unnecessary. Unfortunately, this overuse of antibiotics can cause devastating health consequences to children. Over-reliance on antibiotics is considered to be the main cause for the antibiotic resistance in ENT disorders. According to The National Ambulatory Medical Care Survey (NAMCS), sinusitis is the fifth most common diagnosis for which an antibiotic is prescribed. The increasing pressure on clinicians to reduce antibiotic prescriptions for ENT disorders leaves a therapeutic vacuum.
Antibacterial overuse has also led to short antibacterial drug lifecycles which arises from antibacterial resistance. Short drug lifecycles significantly affect drug developers as they have limited time to recoup their R&D investments. Several major companies cut their development efforts in this market due to factor. On the other hand drug development is initiated by smaller companies in developing innovative drugs or formulations or taking up efforts aborted by the larger companies.
Weak Pipeline Dominated by 'Me-Too' Drugs Marks the ENT Disorders Market
The ENT disorder market drug pipeline is weak, with about 65 products in the various stages of clinical development. Of these, 30 molecules are in Phase III. The pipeline drugs are similar to the marketed drugs in terms of their target and drug delivery systems. The drugs are not expected to replace the revenue losses experienced due to the patent expiries of the blockbuster drugs such as Levaquin, Zithromax and Biaxin.
The pipeline for rhinitis dominates the market for ENT disorders, garnering a considerable share of 71% of the total market. The current ENT disorders pipeline contains 65 projects across five indications. Rhinitis accounts for more than two thirds of the total ENT disorders market and is the key therapy area of focus in the current pipeline.
The tonsillitis and otitis media markets are comparatively smaller. With fewer market opportunities available, pharmaceutical companies do not list these indications as their top priorities. Otitis media drugs occupy 15% of the pipeline, with just 10 projects. Tonsillitis accounts for only 5% of the ENT disorders pipeline. Table of Contents
1. Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2. ENT Disorders Market - Introduction
- 2.1 GBI Research Report Guidance
3. ENT Disorders Market - Market Overview
- 3.1 Rising Global Population and Deteriorating Environmental Conditions Drive ENT Disorder Therapeutics
- 3.2 Gross Maldistribution
- 3.3 ENT Disorders Marked By Antibiotic Overuse
- 3.4 Entry of New Players Restricted by the Number of Generics and Stringent FDA Regulations
- 3.4.1 Ketolides - A New Class of Antibacterials
- 3.5 Revenue Forecasts
- 3.6 Annual Cost of Therapy
- 3.7 Treatment Usage Patterns
- 3.7.1 Diseased Population
- 3.7.2 Treatment Seeking Population
- 3.7.3 Diagnosed Population
- 3.7.4 Prescription Population
- 3.8 Drivers and Restraints of the ENT Disorders Market
- 3.8.1 ENT Disorders Market Drivers
- 3.8.2 ENT Disorders Market Restraints
4. ENT Disorders Market - Therapeutic Landscape
- 4.1 Tonsillitis Market
- 4.1.1 Introduction
- 4.1.2 Revenue Forecasts
- 4.1.3 Annual Cost of Therapy
- 4.1.4 Treatment Flow Algorithm
- 4.1.5 Treatment Usage Patterns
- 4.1.6 Profiles of Key Drugs in the Tonsillitis Market
- 4.1.7 Geographical Segmentation
- 4.2 Sinusitis Market
- 4.2.1 Introduction
- 4.2.2 Revenue Forecasts
- 4.2.3 Annual Cost of Therapy
- 4.2.4 Treatment Flow Algorithm
- 4.2.5 Treatment Usage Patterns
- 4.2.6 Profiles of Key Drugs in the Sinusitis Market
- 4.2.7 Geographical Segmentation
- 4.3 Rhinitis Market
- 4.3.1 Introduction
- 4.3.2 Revenue Forecasts
- 4.3.3 Annual Cost of Therapy
- 4.3.4 Treatment Flow Algorithm
- 4.3.5 Treatment Usage Patterns
- 4.3.6 Profiles of Key Drugs in the Rhinitis Market
- 4.3.7 Geographical Segmentation
- 4.4 Otitis Media Market
- 4.4.1 Introduction
- 4.4.2 Revenue Forecasts
- 4.4.3 Annual Cost of Therapy
- 4.4.4 Treatment Flow Algorithm
- 4.4.5 Treatment Usage Patterns
- 4.4.6 Profiles of Key Drugs in the Otitis Media Market
- 4.4.7 Geographical Segmentation
- 4.5 Tracheobronchitis Market
- 4.5.1 Introduction
- 4.5.2 Revenue Forecasts
- 4.5.3 Annual Cost of Therapy
- 4.5.4 Treatment Flow Algorithm
- 4.5.5 Treatment Usage Patterns
- 4.5.6 Profiles of Key Drugs in the Tracheobronchitis Market
- 4.5.7 Geographical Segmentation
5. ENT Disorders Market - Geographical Landscape
- 5.1 The US
- 5.1.1 Revenue Forecasts
- 5.1.2 Annual Cost of Therapy
- 5.1.3 Treatment Usage Patterns
- 5.2 Top Five Countries in Europe
- 5.2.1 Revenue Forecasts
- 5.2.2 Annual Cost of Therapy
- 5.2.3 Treatment Usage Patterns
- 5.3 Japan
- 5.3.1 Revenue Forecasts
- 5.3.2 Annual Cost of Therapy
- 5.3.3 Treatment Usage Patterns
6. ENT Disorders Market - Pipeline Analysis
- 6.1 Introduction
- 6.1.1 Research and Development Pipeline - Tonsillitis
- 6.1.2 Research and Development Pipeline - Sinusitis
- 6.1.3 Research and Development Pipeline - Rhinitis
- 6.1.4 Research and Development Pipeline - Otitis Media
7. ENT Disorders Market - Competitive Landscape
- 7.1 Competitive Profiling
- 7.1.1 Abbott Laboratories
- 7.1.2 Bayer AG
- 7.1.3 GlaxoSmithKline
- 7.1.4 Johnson & Johnson (J&J)
- 7.1.5 Merck & Co
- 7.1.6 Pfizer
- 7.1.7 Novartis AG
- 7.1.8 F. Hoffmann-La Roche Ltd.
- 7.1.9 Sanofi
8. ENT Disorders Market - Strategic Consolidations
- 8.1 Overview
- 8.2 ENT Disorders Market M&A Deals
- 8.2.1 M&A Deals by Geography
- 8.2.2 Deals by Type
- 8.2.3 Major M&A Deals
- 8.3 R&D Licensing Agreements
- 8.3.1 Deals by Indication
- 8.3.2 Deals by Geography
- 8.3.3 MerLion Pharmaceuticals Enters Into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin
9. ENT Disorders Market - Appendix
- 9.1 Market Definitions
- 9.2 Abbreviations
- 9.3 Research Methodology
- 9.3.1 Coverage
- 9.3.2 Secondary Research
- 9.3.3 Primary Research
- 9.3.4 Geographical Landscape
- 9.3.5 Pipeline Analysis
- 9.3.6 Competitive Landscape
- 9.3.7 Expert Panel Validation
- 9.4 Contact Us
- 9.5 Disclaimer
- 9.6 Sources
List of Tables
- Table 1: ENT Disorders Market, Global, Revenue ($bn), 2002-2010
- Table 2: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017
- Table 3: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2010
- Table 4: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2010-2017
- Table 5: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2010
- Table 6: ENT Disorders Market, Global, Treatment Usage Pattern (million), 2010-2017
- Table 7: ENT Disorders Market, Global, Tonsillitis Revenue ($m), 2002-2010
- Table 8: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2010-2017
- Table 9: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2010
- Table 10: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2010-2017
- Table 11: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2010
- Table 12: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2010-2017
- Table 13: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2010
- Table 14: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2010-2017
- Table 15: ENT Disorders Market, Global, Sinusitis Revenue ($bn), 2002-2010
- Table 16: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2010-2017
- Table 17: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2010
- Table 18: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2010-2017
- Table 19: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2010
- Table 20: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2010-2017
- Table 21: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2002-2010
- Table 22: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2010-2017
- Table 23: ENT Disorders Market, Global, Rhinitis Revenue ($bn), 2002-2010
- Table 24: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2010-2017
- Table 25: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2010
- Table 26: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2010-2017
- Table 27: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2010
- Table 28: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2010-2017
- Table 29: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2002-2010
- Table 30: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2010-2017
- Table 31: ENT Disorders Market, Global, Otitis Media Revenue ($m), 2002-2010
- Table 32: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2010-2017
- Table 33: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2010
- Table 34: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2010-2017
- Table 35: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2010
- Table 36: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2010-2017
- Table 37: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2010
- Table 38: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2010-2017
- Table 39: ENT Disorders Market, Global, Tracheobronchitis Revenue ($m), 2002-2010
- Table 40: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2010-2017
- Table 41: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2010
- Table 42: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2010-2017
- Table 43: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2010
- Table 44: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2010-2017
- Table 45: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2010
- Table 46: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2010-2017
- Table 47: ENT Disorders Market, Global, Revenue by Geography ($bn), 2002-2010
- Table 48: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2010-2017
- Table 49: ENT Disorders Market, The US, Revenue ($bn), 2002-2010
- Table 50: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2010-2017
- Table 51: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2010
- Table 52: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2010-2017
- Table 53: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2010
- Table 54: ENT Disorders Market, The US, Treatment Usage Patterns (million), 2010-2017
- Table 55: ENT Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002-2010
- Table 56: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010-2017
- Table 57: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
- Table 58: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
- Table 59: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2010
- Table 60: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010-2017
- Table 61: ENT Disorders Market, Japan, Revenues ($m), 2002-2010
- Table 62: ENT Disorders Market, Japan, Revenues ($m), 2010-2017
- Table 63: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2010
- Table 64: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2010-2017
- Table 65: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2010
- Table 66: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2010-2017
- Table 67: ENT Disorders Market, Global, Tonsillitis Phase III Clinical Pipeline, 2011
- Table 68: ENT Disorders Market, Global, Sinusitis Phase III Clinical Pipeline, 2011
- Table 69: ENT Disorders Market, Global, Rhinitis Phase III Clinical Pipeline, 2011
- Table 70: ENT Disorders Market, Global, Rhinitis Phase II Clinical Pipeline, 2011
- Table 71: ENT Disorders Market, Global, Rhinitis Phase I Clinical Pipeline, 2011
- Table 72: ENT Disorders Market, Global, Rhinitis Pre-clinical Pipeline, 2011
- Table 73: ENT Disorders Market, Global, Otitis Media, Regulatory Filing and Phase III Clinical Pipeline, 2011
List of Figures
- Figure 1: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017
- Figure 2: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2017
- Figure 3: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2017
- Figure 4: ENT Disorders Market, Global, Diseased Population (million), 2002-2017
- Figure 5: ENT Disorders Market, Global, Treatment Seeking Population (million), 2002-2017
- Figure 6: ENT Disorders Market, Global, Diagnosis Population (million), 2002-2017
- Figure 7: ENT Disorders Market, Global, Prescription Population (million), 2002-2017
- Figure 8: ENT Disorders Market, Global, Drivers and Restraints, 2011
- Figure 9: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2002-2017
- Figure 10: ENT Disorders Market, Global, Tonsillitis Therapeutics Market, Branded and Generic Share, (%), 2010
- Figure 11: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2017
- Figure 12: ENT Disorders Market, Global, Tonsillitis, Treatment Flow Algorithm
- Figure 13: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2017
- Figure 14: ENT Disorders Market, Global, Tonsillitis Diseased Population (million), 2002-2017
- Figure 15: ENT Disorders Market, Global, Tonsillitis Treatment Seeking Population (million), 2002-2017
- Figure 16: ENT Disorders Market, Global, Tonsillitis Diagnosis Population (million), 2002-2017
- Figure 17: ENT Disorders Market, Global, Tonsillitis Prescription Population (million), 2002-2017
- Figure 18: ENT Disorders Market, Global, Tonsillitis Market Segmentation by Geography, (%), 2010 and 2017
- Figure 19: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2017
- Figure 20: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2002-2017
- Figure 21: ENT Disorders Market, Global, Sinusitis Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
- Figure 22: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2017
- Figure 23: ENT Disorders Market, Global, Sinusitis, Treatment Flow Algorithm
- Figure 24: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2017
- Figure 25: ENT Disorders Market, Global, Sinusitis Diseased Population (million), 2002-2017
- Figure 26: ENT Disorders Market, Global, Sinusitis Treatment Seeking Population (million), 2002-2017
- Figure 27: ENT Disorders Market, Global, Sinusitis Diagnosed Population (million), 2002-2017
- Figure 28: ENT Disorders Market, Global, Sinusitis Prescription Population (million), 2002-2017
- Figure 29: ENT Disorders Market, Global, Sinusitis Market Segmentation by Geography, 2010 and 2017
- Figure 30: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($bn), 2002-2017
- Figure 31: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2002-2017
- Figure 32: ENT Disorders Market, Global Rhinitis, Branded and Generic Share, (%), 2010 and 2017
- Figure 33: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2017
- Figure 34: ENT Disorders Market, Global, Rhinitis, Treatment Flow Algorithm
- Figure 35: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2017
- Figure 36: ENT Disorders Market, Global, Rhinitis Diseased Population (million), 2002-2017
- Figure 37: ENT Disorders Market, Global, Rhinitis Treatment Seeking Population (million), 2002-2017
- Figure 38: ENT Disorders Market, Global, Rhinitis Diagnosis Population (million), 2002-2017
- Figure 39: ENT Disorders Market, Global, Rhinitis Prescription Population (million), 2002-2017
- Figure 40: ENT Disorders Market, Global, Rhinitis Market Segmentation by Geography, 2010 and 2017
- Figure 41: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2002-2017
- Figure 42: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2002-2017
- Figure 43: ENT Disorders Market, Global, Otitis Media Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
- Figure 44: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2017
- Figure 45: ENT Disorders Market, Global, Otitis Media, Treatment Flow Algorithm
- Figure 46: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2017
- Figure 47: ENT Disorders Market, Global, Otitis Media, Causes (%), 2011
- Figure 48: ENT Disorders Market, Global, Otitis Media Diseased Population (million), 2002-2017
- Figure 49: ENT Disorders Market, Global, Otitis Media Treatment Seeking Population (million), 2002-2017
- Figure 50: ENT Disorders Market, Global, Otitis Media Diagnosed Population (million), 2002-2017
- Figure 51: ENT Disorders Market, Global, Otitis Media Prescription Population (million), 2002-2017
- Figure 52: ENT Disorders Market, Global, Otitis Media Market Segmentation by Geography, (%), 2010 and 2017
- Figure 53: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2017
- Figure 54: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2002-2017
- Figure 55: ENT Disorders Market , Global, Tracheobronchitis Therapeutics Market, Branded and Generic Share (%), 2010 and 2017
- Figure 56: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2017
- Figure 57: ENT Disorders Market, Global, Tracheobronchitis, Treatment Flow Algorithm
- Figure 58: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2017
- Figure 59: ENT Disorders Market, Global, Tracheobronchitis Diseased Population (million), 2002-2017
- Figure 60:ENT Disorders Market, Global, Tracheobronchitis Treatment Seeking Population (million), 2002-2017
- Figure 61: ENT Disorders Market, Global, Tracheobronchitis Diagnosed Population (million), 2002-2017
- Figure 62: ENT Disorders Market, Global, Tracheobronchitis Prescription Population (million), 2002-2017
- Figure 63: ENT Disorders Market, Global, Tracheobronchitis Market Segmentation by Geography, 2010 and 2017
- Figure 64: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2017
- Figure 65: ENT Disorders Market, Global, Market Share by Geography, (%), 2010 and 2017
- Figure 66: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2002-2017
- Figure 67: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2002-2017
- Figure 68: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2017
- Figure 69: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2017
- Figure 70: ENT Disorders Market, The US, Diseased Population (million), 2002-2017
- Figure 71: ENT Disorders Market, The US, Treatment Seeking Population (million), 2002-2017
- Figure 72: ENT Disorders Market, The US, Diagnosed Population (million), 2002-2017
- Figure 73: ENT Disorders Market, The US, Prescription Population (million), 2002-2017
- Figure 74: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002-2017
- Figure 75: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
- Figure 76: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2017
- Figure 77: ENT Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2002-2017
- Figure 78: ENT Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002-2017
- Figure 79: ENT Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2002-2017
- Figure 80: ENT Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2002-2017
- Figure 81: ENT Disorders Market, Japan, Revenues ($m), 2002-2017
- Figure 82: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2017
- Figure 83: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2017
- Figure 84: ENT Disorders Market, Japan, Diseased Population (million), 2002-2017
- Figure 85: ENT Disorders Market, Japan, Treatment Seeking Population (million), 2002-2017
- Figure 86: ENT Disorders Market, Japan, Diagnosis Population (million), 2002-2017
- Figure 87: ENT Disorders Market, Japan, Prescription Population (million), 2002-2017
- Figure 88: ENT Disorders Market, Global, R&D Pipeline by Indication (%), 2011
- Figure 89: ENT Disorders Market, Global, R&D Pipeline by Phase (%), 2011
- Figure 90: ENT Disorders Market, Global, R&D Pipeline by Phase in Sinusitis Market (%), 2011
- Figure 91: ENT Disorders Market, Global, R&D Pipeline by Phase in Rhinitis Market (%), 2011
- Figure 92: ENT Disorders Market, Global, R&D Pipeline by Phase in Otitis Media (%), 2011
- Figure 93: ENT Disorders Market, Global, SWOT - Abbott Laboratories, 2011
- Figure 94: ENT Disorders Market, Global, SWOT - Bayer AG, 2011
- Figure 95: ENT Disorders Market, Global, SWOT - GSK, 2011
- Figure 96: ENT Disorders Market, Global, SWOT - Johnson & Johnson, 2011
- Figure 97: ENT Disorders Market, Global, SWOT - Merck, 2011
- Figure 98: ENT Disorders Market, Global, SWOT - Pfizer, 2011
- Figure 99: ENT Disorders Market, Global, SWOT - Novartis, 2011
- Figure 100: ENT Disorders Market, Global, SWOT - Roche, 2011
- Figure 101: ENT Disorders Market, Global, SWOT- Sanofi, 2011
- Figure 102: ENT Disorders Market, Global, M&A Deals by Indication (%), 2004-2011
- Figure 103: ENT Disorders Market, Global, Major M&A Deals By Geography (%), 2004-2011
- Figure 104: ENT Disorders Market, Global, Major M&A Deals By Type (%), 2004-2011
- Figure 105: ENT Disorders Market, Global, Licensing Deals by Indication (%), 2004-2011
- Figure 106: ENT Disorders Market, Global, Licensing Deals By Geography, (%), 2004-2011
- Figure 107: GBI Research Market Forecasting Model
|
 |
